|
|
Volumn 482, Issue 7384, 2012, Pages 145-
|
|
Drug bests cystic-fibrosis mutation
a
a
NONE
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
IVACAFTOR;
KALYDECO;
PLACEBO;
TRANSMEMBRANE CONDUCTANCE REGULATOR;
UNCLASSIFIED DRUG;
CONTROLLED CLINICAL TRIAL (TOPIC);
CYSTIC FIBROSIS;
DRUG EFFICACY;
DRUG INDUSTRY;
GENE DELETION;
GENE MUTATION;
HUMAN;
LUNG FIBROSIS;
NONHUMAN;
NOTE;
PRIORITY JOURNAL;
PROTEIN FUNCTION;
TREATMENT OUTCOME;
CYSTIC FIBROSIS;
CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR;
HUMANS;
MOLECULAR TARGETED THERAPY;
MUTANT PROTEINS;
MUTATION;
|
|
EID: 84856949953
PISSN: 00280836
EISSN: 14764687
Source Type: Journal
DOI: 10.1038/482145a Document Type: Note |
|
Times cited : (16)
|
|
References (0)
|
